CJC-1295 isn't stocked on pharmacy shelves in Khanr or virtually any local market — it's a research compound available through a dedicated online market. This matters because CJC-1295 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to products with serious contamination — and the vendor is the entire quality system. What reliably differentiates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. The sections below cover what Khanr researchers need to know about purchasing, testing, and working with CJC-1295 for research purposes.
Understanding CJC-1295 — Biology & Evidence
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Khanr comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before evaluating any specific vendor, establish a quality benchmark — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are within acceptable research limits. For Khanr researchers evaluating new suppliers: a small initial order to verify quality before placing larger orders is the accepted approach among experienced researchers. Price is an unreliable primary filter for CJC-1295 quality — research-grade synthesis and testing has unavoidable expenses that low-priced vendors are not absorbing, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Khanr
COA-verified · International tracking · Research grade
All use of CJC-1295 in Khanr or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Proper handling of CJC-1295 requires sterile reconstitution technique — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that verified-quality sourcing directly prevents. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is unapproved for human therapeutic application and its risk profile is not equivalent to approved medications.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
